Abstract
BackgroundReferrals to clinical trials of novel agents in stage IV gastroesophageal adenocarcinoma are conventionally placed after standard options are exhausted, although immune checkpoint inhibitors and other monoclonal antibodies now produce durable remissions in this setting. The convention has been questioned by the US Food and Drug Administration initiative Project FrontRunner but has not been quantified for any tumor type.MethodsThis modeling study combined 2022 global incidence estimates, stage-at-diagnosis fractions and real-world line-of-therapy patterns from four health-system contexts to estimate patients reaching each successive line annually. Effect estimates came from every published phase 3 trial reporting a 24-month progression-free survival (PFS) landmark. The outcome was patients per year worldwide progression-free at 24 months who would not otherwise be, calculated as the between-arm difference in 24-month PFS multiplied by patients reaching that line.ResultsAn estimated 1,050,553 new gastroesophageal adenocarcinomas occurred worldwide annually; approximately 693,761 patients had stage IV disease and 504,711 received first-line therapy. The population contracted 9.9-fold between first and third line, to 50,991. Four first-line phase 3 trials spanning two drug classes yielded consistent 24-month PFS differences of 7.0–9.0 percentage points (mean 8.22), corresponding to approximately 41,512 patients per year with durable non-progression versus approximately 9,016 at second line and at most 4,436 at third: 4.6-fold and at least 9.4-fold more, respectively.ConclusionThe benefit forfeited by last-resort trial positioning was large and was attributable almost entirely to patient exposure rather than per-patient drug activity, and was most pronounced where access to later lines is limited.